R

REGENXBIO
D

RGNX

7.63000
USD
0.22
(2.97%)
Market Closed
Volume
124,618
EPS
-5
Div Yield
-
P/E
-2
Market Cap
378,028,892
OverviewSignalsIdeasNews
Related Instruments
    ALNY
    ALNY
    6.675
    (2.79%)
    245.505 USD
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    E
    EDIT
    -0.01000
    (-0.75%)
    1.32000 USD
    N
    NTLA
    0.120
    (0.99%)
    12.190 USD
    Q
    QURE
    1.550
    (10.00%)
    17.050 USD
    R
    RARE
    0.770
    (1.77%)
    44.190 USD
    S
    SGMO
    0.17500
    (7.56%)
    2.49000 USD
    S
    SRPT
    -0.470
    (-0.39%)
    118.970 USD
    VRTX
    VRTX
    0.58
    (0.15%)
    397.15 USD
    More
News

Title: REGENXBIO

Sector: Healthcare
Industry: Biotechnology
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.